Spaulding Clinical Announces COO Cassandra Erato Will Succeed Randy Spaulding as CEO

WEST BEND, Wis. (February 6, 2020) – Spaulding Clinical Research announced today that it has named Cassandra Erato chief executive officer, effective February 1, 2020. Randy Spaulding will assume the role of founder, chairman, and chief visionary officer.

“I am honored to assume leadership of Spaulding Clinical. Mr. Spaulding built our Phase 1 site based on the vision of building the first fully paperless Phase 1 CRO and a world-class cardiac safety testing site,” said Erato. “He was clearly 10 years ahead of his time, as we’ve seen other Phase 1 units start to adopt eSource solutions in the past year. He has introduced many new functionalities and integrations; recently, he introduced a new functionality that allows us to deliver flash results faster than anyone in the industry. I am committed to continuing to grow Spaulding Clinical and build upon the excellent foundation that has been laid.”

Randy Spaulding will continue an active role as managing member and will focus on the next innovations of the company.

“Our vision is to continue to deliver new technologies that enable our customers to make decisions faster and bring new, life-enhancing drugs to market faster than before,” said Spaulding. “Mrs. Erato is the best person to execute on this vision and help us achieve our next phase of growth. This enables me to focus even more time on developing new technologies for the pharmaceutical development industry.”

Mrs. Erato is currently the COO of Spaulding Clinical and has held the position since 2015. She has been with Spaulding Clinical since its inception in 2007 and has played a key role in developing the operational procedures and systems in place today.

Erato will be attending SCOPE 2020 in Orlando, Florida, the week of February 17 and is available for interviews.

 

About Spaulding Clinical Research
Spaulding Clinical opened in 2007 and was built upon fully electronic data and integrated, purposefully engineered systems for conducting Phase I trials. Spaulding runs a 200-bed facility in West Bend, Wis., and conducts and analyzes first-in-human, clinical proof-of-concept, cardiovascular safety (TQT, concentration effect) and NDA-enabling clinical pharmacology studies. Spaulding Clinical provides expertise on study design, medical writing, clinical data management, biostatistics and PK/PD analysis. Learn more at spauldingclinical.com.